Related Experiment Video
Updated: Feb 11, 2026
Intracranial Pharmacotherapy and Pain Assays in Rodents
Published on: April 9, 2019
Pharmacotherapy and ROP: Going Back to the Basics
Julia P Shulman1, M Elizabeth Hartnett2
1New York Medical College, Turo, Valhalla, NY.
Insights
Retinopathy of prematurity (ROP) is a major cause of blindness in premature infants. This review covers ROP pathophysiology and current pharmacotherapy, highlighting evolving treatment strategies beyond laser therapy.
Area of Science:
- Ophthalmology
- Neonatology
- Developmental Biology
Background:
- Retinopathy of prematurity (ROP) is a significant cause of vision impairment in preterm infants globally.
- Understanding of ROP pathophysiology has advanced through animal models and clinical studies since its initial description.
- Current treatments primarily involve laser therapy, but pharmacologic interventions are increasingly utilized.
Purpose of the Study:
- To summarize the current understanding of Retinopathy of prematurity pathophysiology.
- To discuss contemporary therapeutic strategies for ROP, focusing on pharmacotherapy.
- To review emerging targets for pharmacologic treatment of ROP.
Main Methods:
- Review of data from animal models of ROP.
- Analysis of findings from clinical trials in ROP.
- Synthesis of current literature on ROP pathophysiology and treatment.
Main Results:
- Animal models have been crucial in elucidating ROP disease mechanisms.
- Pharmacotherapy is becoming a more common treatment modality for ROP.
- New targets for drug development in ROP treatment are emerging.
Conclusions:
- Continued research into ROP pathophysiology is essential for advancing treatment.
- Pharmacologic agents represent a growing and important component of ROP management.
- Future therapies may offer improved outcomes for preterm infants at risk of ROP.
Abstract:
Retinopathy of prematurity (ROP) is a leading cause of blindness in preterm infants around the world. Through the development of animal models and clinical trials our understanding of the pathophysiology of this disease and approach to therapy has evolved significantly since ROP was first described in the 1940s in the United States. The mainstay of treatment in ROP remains ablative laser therapy to the avascular retina but pharmacologic agents are being more and more commonly used with new targets for pharmacotherapy emerging. This paper summarizes our current understanding of the pathophysiology of ROP based on the data gleaned from animal models and discusses current approaches to pharmacotherapy.
Related Concept Videos
01:26Psychosis: Goals of Pharmacotherapy
01:15Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
02:27Energy Basics
01:21Basicity of Aliphatic Amines
To measure the basicity of amines, two conventions are generally used. The first defines Kb as the basicity constant for the deprotonation reaction of water by the amine, as presented in Figure 1. Conventionally, lower Kb indicates higher...
01:22Basic Operations on Signals
Time Reversal mirrors a continuous-time signal about the vertical axis at t=0. This is achieved by substituting t with −t. For example, if a signal x(t) is considered, the time-reversed signal is x(−t). This operation can be graphically represented, showing the mirrored signal.
02:52VSEPR Theory and the Basic Shapes